These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
4. Reproducibility of F18-FDG PET radiomic features for different cervical tumor segmentation methods, gray-level discretization, and reconstruction algorithms. Altazi BA; Zhang GG; Fernandez DC; Montejo ME; Hunt D; Werner J; Biagioli MC; Moros EG J Appl Clin Med Phys; 2017 Nov; 18(6):32-48. PubMed ID: 28891217 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma. Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273 [TBL] [Abstract][Full Text] [Related]
7. Radiomics for the Prediction of Treatment Outcome and Survival in Patients With Colorectal Cancer: A Systematic Review. Staal FCR; van der Reijd DJ; Taghavi M; Lambregts DMJ; Beets-Tan RGH; Maas M Clin Colorectal Cancer; 2021 Mar; 20(1):52-71. PubMed ID: 33349519 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of an Wang H; Zhao S; Li L; Tian R Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928 [TBL] [Abstract][Full Text] [Related]
10. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763 [TBL] [Abstract][Full Text] [Related]
11. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346 [TBL] [Abstract][Full Text] [Related]
12. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511 [TBL] [Abstract][Full Text] [Related]
13. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Littooij AS; Kwee TC; Barber I; Granata C; Vermoolen MA; Enríquez G; Zsíros J; Soh SY; de Keizer B; Beek FJ; Hobbelink MG; Bierings MB; Stoker J; Nievelstein RA Eur Radiol; 2014 May; 24(5):1153-65. PubMed ID: 24563179 [TBL] [Abstract][Full Text] [Related]
14. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135 [TBL] [Abstract][Full Text] [Related]
15. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT. Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444 [TBL] [Abstract][Full Text] [Related]
18. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008 [TBL] [Abstract][Full Text] [Related]
19. Radiogenomics and Its Role in Lymphoma. Khan S; Naim S; Bilwani R; Salem A; Gorlin D; Muhammad A; Gul M; Imam MH; Chaudhry A Curr Hematol Malig Rep; 2020 Jun; 15(3):211-224. PubMed ID: 32430588 [TBL] [Abstract][Full Text] [Related]